How does cancer innovation reach patients? A panel with David Gauden of Blue Earth Therapeutics and Dr Ben Riley of NHS Thames Valley ICB.

How do we turn cancer innovation into patient access?

Join Oxford Oncology Society for Panel II of From Policy to Access, bringing together perspectives from biotech and NHS leadership.

David Gauden — Chief Executive Officer, Blue Earth Therapeutics

A co-founder of Blue Earth Diagnostics with more than 25 years in radiopharmaceuticals, David leads Blue Earth Therapeutics, which completed a US$76.5 million Series A financing round in October 2024 to advance targeted radioligand therapies for prostate cancer.

Dr Ben Riley — Executive Medical Director, NHS Thames Valley Integrated Care Board

Ben brings a health-system perspective on clinical strategy, innovation, governance and improving health outcomes.

Part of our Weekly Cancer Perspectives programme, this panel explores how governance, regulation, commercial interests and socioeconomic factors shape cancer care and access.

Week 2 · Michaelmas 2026

Thursday, 22 October 2026 · 7:00–8:00 pm BST

Dorfman Centre, St Peter’s College

New Inn Hall Street, Oxford OX1 2DL

Free admission. Find out more at oxonco.org.

Charity raffle

Two lucky winners at each event will receive £50 each. A random draw will take place at the end of the event using Wheel of Names. For every £50 prize, we donate another £50 to Cancer Research UK in the winner’s name. Limited to the first 30 registrants for each event.

Registration is also available on Luma. Please book through only one platform.

Description supplied by the event organiser.